the literature, per channel

What to expect from this page

This page works through three separate research literatures — one per GLOW component — rather than treating the blend as a single thing that has been studied, because it has not been. GHK-Cu has the deepest research record of the three, anchored in cosmetic dermatology and wound-healing biology, with one controlled diabetic-ulcer trial from 1994 and a large body of cell-culture and transcriptomic work since. BPC-157 has an extensive rodent dataset and three small human pilots, the most recent of which was a 2-subject intravenous safety report from 2025. TB-500 inherits almost all of its evidence base from the full-length parent protein (thymosin beta-4), not from the commercial seventeen-residue fragment itself. Reading these three channels in sequence gives you the honest picture of what GLOW actually means in the indexed literature: three independently studied signals, zero studies of the three together.

How this page is organized

The GLOW blend is three molecules. The research literature is three datasets. This page works through them in order — channel R (GHK-Cu), channel G (BPC-157), channel B (TB-500) — then ends at the place the literature ends, which is the absence of any combination trial. Every quantitative claim cites a specific paper in the references index.

The taxonomy is structural, not editorial. We do not weigh evidence across channels (you cannot meaningfully compare a 1994 diabetic-ulcer wound-closure rate to a 2025 narrative-review pilot count), and we do not rank the components against one another. We summarize what each has been studied for, in what model, at what dose, with what result.

Channel R — GHK-Cu (extracellular matrix and wound healing)

GHK-Cu is the deepest-studied of the three components, primarily in cosmetic dermatology and wound-healing contexts. The molecule is a glycyl-L-histidyl-L-lysine tripeptide chelated to a single copper(II) ion, with a molecular weight of about 340.8 daltons. Its native concentration in human plasma declines with age, a quiet biographical detail that has anchored most of the regenerative interest ^[2].

The most-cited human evidence is a 1994 Mulder study of topical GHK-Cu (formulated as a 'lamin' gel) applied twice daily to diabetic neuropathic foot ulcers. Wound closure ran roughly three times faster than placebo (P<0.01), and the treatment group had a lower infection rate ^[1]. The trial is now thirty years old, but it remains the most-cited controlled human result for the tripeptide.

The mechanistic interest accelerated in 2014 with Pickart's Connectivity Map analysis. At 1-10 nM in cell culture, GHK-Cu shifted expression of about thirty-one percent of measured human genes (defined as a fifty-percent or greater change at twenty-four hours), with fifty-nine percent of those genes upregulated ^[2]. The affected programs cluster around matrix synthesis (collagen, elastin, decorin, dermatan and chondroitin sulfate), antioxidant defense, and DNA repair. The framing in the paper — 'resetting the human genome to health' — is rhetorical; the underlying transcriptomic signal is real but its therapeutic translation remains a research question, not a settled finding.

In vivo, intraperitoneal GHK-Cu has been studied in mouse models of acute lung injury and bleomycin-induced pulmonary fibrosis. The peptide reduced TNF-alpha and IL-6 output, attenuated lung-injury histology ^[3], and reversed MMP-9 / TIMP-1 imbalance via NF-kB and TGF-beta1 pathways in the fibrosis model ^[4]. The pattern across the in vitro and animal work is consistent: GHK-Cu rebalances inflammatory and matrix-turnover programs rather than dramatically pushing any single pathway.

In hair-follicle research, a tripeptide-copper complex stimulated dermal papilla cell proliferation, raised VEGF, lowered TGF-beta1, and promoted elongation of human hair follicles ex vivo at picomolar-to-nanomolar concentrations ^[5]. The recent formulation literature — including 2025 work on liposomal encapsulation — addresses the longstanding bioavailability constraint that has limited topical delivery of free GHK-Cu ^[17].

What the GHK-Cu literature does not yet contain is a large modern randomized trial in any indication. The 1994 wound study has not been replicated at scale. Cosmetic-dermatology evidence is broader but methodologically uneven, and the bulk of mechanistic insight remains in vitro.

Channel G — BPC-157 (angiogenesis, tendon, gut-brain axis)

BPC-157 — Body Protection Compound 157, also called PL-14736 in its earlier clinical-development incarnation — is a fifteen-amino-acid pentadecapeptide derived from a protective protein in human gastric juice. Sequence GEPPPGKPADDAGLV. The peptide is notably stable in human gastric juice (which is, after all, its native environment), and that stability has underwritten the persistent interest in oral and gastrointestinal delivery.

The most-replicated mechanism is angiogenesis through the VEGFR2-Akt-eNOS pathway. BPC-157 upregulates expression and endocytosis of vascular endothelial growth factor receptor 2 on endothelial cells; downstream phosphorylation of Akt activates endothelial nitric oxide synthase, increasing nitric oxide release and driving capillary sprouting into healing tissue ^[8]. A related 2020 paper traced the same vascular biology to a Src-Caveolin-1-eNOS pathway in rat ischemia models, where 10 µg/kg intraperitoneal BPC-157 restored vasomotor function ^[8].

In tendon biology, intraperitoneal BPC-157 at 10 µg/kg accelerated tendon outgrowth, cell survival, and cell migration in a transected Achilles tendon model in rats ^[7]. A parallel in vitro study found that BPC-157 dose- and time-dependently upregulated growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels, potentiating GH-driven proliferation ^[6]. The tendon evidence base is the strongest signal in the BPC-157 dataset, but it remains rodent-only with the exception of small pilot work.

The Sikiric group has spent the last decade building a unifying framework in which BPC-157 acts as a cytoprotection mediator with neurotransmitter-like activity, simultaneously modulating dopaminergic, serotonergic, glutamatergic, GABAergic, and nitric-oxide systems via the brain-gut axis ^[10]. A 2025 follow-up reframed the angiogenic mechanism as selective modulation — sparing protective NO functions while blunting cytotoxic ones — in response to a 2025 narrative review that raised safety questions ^[18].

That 2025 narrative review by McGuire and colleagues is the current state-of-the-art human-evidence synthesis. Through March 2025, the authors found robust preclinical evidence for accelerated tendon, ligament, muscle, and bone healing, but only three pilot human studies in the indexed literature: knee pain (n=14, 87.5% relief), interstitial cystitis (n=12, 80-100% symptom resolution), and an intravenous safety report (n=2) ^[9]. The authors emphasize that BPC-157 must continue to be considered investigational.

The most-cited gap in the BPC-157 human evidence is the unpublished Phase II Pliva trial. The compound, then under the development name PL-14736, advanced into a Phase II multicenter, randomized, double-blind, placebo-controlled enema trial for mild-to-moderate ulcerative colitis. The trial completed; full results were never published in a peer-reviewed journal ^[16]. The gap is sometimes described in lay sources as a 'terminated' trial; the more accurate framing is 'completed without peer-reviewed publication.'

Channel B — TB-500 (thymosin beta-4 fragment, migration and ophthalmology)

TB-500 is a seventeen-amino-acid synthetic peptide corresponding to residues 1-17 of full-length thymosin beta-4 (Tβ4), a forty-three-amino-acid peptide that sequesters monomeric G-actin and maintains the free actin pool that cells draw on for cytoskeletal remodeling ^[11]. The fragment inherits the actin-binding domain; the broader thymosin beta-4 clinical record carries most of the supporting context.

The canonical biochemistry: full-length Tβ4 binds G-actin one-to-one with nanomolar affinity, maintaining a cytoplasmic pool of unpolymerized actin available for rapid F-actin assembly during migration ^[11]. This is the mechanism that underwrites the migration-promoting effects across multiple cell types — keratinocytes, fibroblasts, endothelial cells, myoblasts.

In 2004, Bock-Marquette and colleagues reported in Nature that intraperitoneal Tβ4 after coronary ligation in mice activated integrin-linked kinase and Akt, promoted cardiac cell migration and survival, and improved left-ventricular function — the first molecule, they argued, to initiate simultaneous myocardial and vascular regeneration after systemic administration ^[13]. In a 2010 rat embolic stroke model, Tβ4 at 6 mg/kg intraperitoneal starting twenty-four hours post-stroke (every three days, four doses) improved neurological score, increased oligodendrocyte progenitor cells, and increased axonal density ^[14]. In a 2011 mouse muscle-injury study, endogenously released Tβ4 acted as a chemoattractant for myoblasts, drawing them into damaged muscle tissue ^[15].

The strongest human data sits in ophthalmology. A 2023 randomized, placebo-controlled, double-masked Phase III trial of 0.1% RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy reported increased complete corneal healing versus placebo and improved patient-reported comfort over twenty-eight days of multi-daily dosing ^[12]. A 2024 engineered tandem-Tβ4 construct improved manufacturability and accelerated corneal re-epithelialization in animal models versus monomeric Tβ4 [unpublished extension reported in PMC] — a sign that the parent molecule's translational program remains active.

What the TB-500 fragment specifically does not yet have is a published clinical trial in any indication. The clinical record belongs to full-length thymosin beta-4. Extrapolation from the parent peptide to the seventeen-residue fragment is reasonable mechanistically (the actin-binding domain is conserved) but is not the same as evidence.

The unstudied combination

And then there is the white space.

No peer-reviewed clinical or preclinical study has tested the full GHK-Cu + BPC-157 + TB-500 combination as a single intervention ^[16]. The synergy rationale is mechanistic: matrix remodeling, capillary supply, and cell migration are three sequential requirements of wound repair, so co-administration might compress the timeline. Each component's individual record supports the per-channel claim. The cross-channel interaction does not appear in the indexed literature.

This matters more than it might sound. Combination pharmacology is not a sum of monotherapies. Dose-response curves shift. Pharmacokinetic interactions emerge. Mechanistic effects can amplify or cancel. None of those questions have been studied for GLOW. The community-derived 'GLOW' label travels through vendor catalogs and forum posts without ever passing through a randomized trial.

The two-component BPC-157 + TB-500 subset — sometimes nicknamed 'Wolverine' — is the most-cited stack in the lay literature, but it too lacks a controlled combination trial. What exists is a parallel set of single-component studies that practitioners pattern-match into a stack ^[16].

The honest summary: three components, three independent evidence bases, zero peer-reviewed combination studies. The site reflects this structure in its visual vocabulary — three channels that almost-but-do-not-quite register — because that asymmetry between component evidence and combination evidence is the most important thing a reader can leave this page knowing.